CEO Vincent Angotti highlighted significant progress in the NEPHRO CRRT study, emphasizing the FDA-approved reduction in study size from 166 to 70 patients while maintaining 90% statistical power for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback